Gain Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A novel approach to Parkinson's targets disease biology by stabilizing GCase, with early clinical data showing safety, biomarker engagement, and stable motor scores. Phase II trials will stratify patients by biomarkers and begin in Q3, with further pipeline candidates in development.
-
GT-02287 showed promising biomarker and clinical signals in a phase 1b Parkinson's study, with reductions in CSF glucosylsphingosine correlating to UPDRS improvements. The drug's mechanism targets GCase pathway dysfunction, and further validation in phase II is planned.
Fiscal Year 2025
-
A phase I-B study of GT-02287 in Parkinson's disease shows favorable safety and early signs of clinical improvement, with most adverse events mild and a majority of patients entering a nine-month extension. Biomarker and full clinical data are expected by year-end, with a phase II trial planned for next year.
Fiscal Year 2024
-
GT-02287, a GCase modulator, is advancing to Phase 1b trials in both GBA1 and idiopathic Parkinson's patients after promising human and preclinical data. The drug aims to modify disease progression by targeting cellular mechanisms, with initial results expected in the first half of next year.
-
Leadership transitioned to an interim CEO and executive chairman, with no change in strategy. Recent $11 million financing supports ongoing clinical development of GT-02287 for Parkinson's disease, with key trial results and a Phase 1b study upcoming.